PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia

Cell Death and Differentiation

Volumn 23, Issue 6, 2016, Pages 1049-1059

  Guirguis, A A ^a,b   Slape, C I ^a   Failla, L M ^c   Saw, J ^a   Tremblay, C S ^a   Powell, D R ^a   Rossello, F ^a   Wei, A ^a,b   Strasser, A ^d   Curtis, D J ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE H2AX; HYBRID PROTEIN; NUP98 HOXD13 FUSION PROTEIN; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; NUP98-HOXD13 PROTEIN, HUMAN; ONCOPROTEIN; PMAIP1 PROTEIN, MOUSE; PROTEIN BCL 2; PUMA PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; DNA DAMAGE; ERYTHROID CELL; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; KNOCKOUT MOUSE; LEUKEMOGENESIS; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; STEM CELL EXPANSION; UPREGULATION; ACUTE MYELOID LEUKEMIA; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CYTOLOGY; DEFICIENCY; DISEASE EXACERBATION; DISEASE MODEL; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHENOTYPE; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA DAMAGE; HEMATOPOIETIC STEM CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELODYSPLASTIC SYNDROMES; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84953455395     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.159     Document Type: Article

References (44)

1. Bravo GM, Lee E, Merchan B, Kantarjian HM, Garcia-Manero G. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol 2014; 166: 646-659
2. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL., et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA 2013; 110: 3011-3016
3. Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014; 25: 794-808
4. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012; 12: 849-859
5. Kerbauy D, Deeg H. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007; 35: 1739-1746
6. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL., et al. A p53- dependent mechanism underlies macrocytic anemia in a mouse model of human 5qsyndrome. Nat Med 2010; 16: 59-66
7. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C., et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011; 117: 2567-2576
8. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
10. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333
11. Vandenberg CJ,Waring P, Strasser A, Cory S. Plasmacytomagenesis in E?-v-Abl transgenic mice is accelerated when apoptosis is restrained. Blood 2014; 124: 1099-1109
12. Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK., et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009; 16: 684-696
13. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC., et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013; 160: 660-672
14. Valente LJ, Gray DHD, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL., et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339-1345
15. Lin YW, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005; 106: 287-295
16. Slape C, Liu LY, Beachy S, Aplan PD. Leukemic transformation in mice expressing a NUP98- HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood 2008; 112: 2017-2019
17. Slape CI, Saw J, Jowett JBM, Aplan PD, Strasser A, Jane SM., et al. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. Blood 2012; 120: 2475-2483
18. Xu H, Menendez S, Schlegelberger B, Bae N, Aplan PD, Göhring G., et al. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model. Blood 2012; 120: 3089-3097
19. Chung YJ, Choi CW, Slape C, Fry T, Aplan PD. Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. Proc Natl Acad Sci USA 2008; 105: 14088-14093
20. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822
21. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431
22. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335-339
23. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD., et al. Anti-Apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26: 120-125
24. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676
25. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403
26. Jeffers JR, Parganas E, Lee Y, Yang C,Wang J, Brennan J., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321-328
27. Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt B, Pagenstecher A., et al. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep 2013; 3: 1512-1525
28. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G., et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-1979
29. Akala OO, Park I-K, Qian D, Pihalja M, Becker MW, Clarke MF. Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature 2008; 453: 228-23
30. Jabbour AM, Daunt CP, Green BD, Vogel S, Gordon L, Lee RS., et al. Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation. Blood 2010; 115: 344-352
31. Michalak EM, Vandenberg CJ, Delbridge ARD, Wu L, Scott CL, Adams JM., et al. Apoptosispromoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev 2010; 24: 1608-1613
32. Shao L, Sun Y, Zhang Z, Feng W, Gao Y, Cai Z., et al. Deletion of proapoptotic Puma selectively protects hematopoietic stem and progenitor cells against high-dose radiation. Blood 2010; 115: 4707-4714
33. Wu W-S, Heinrichs S, Xu D, Garrison SP, Zambetti GP, ADAMS JM., et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005; 123: 641-653
34. Yu H, Shen H, Yuan Y, XuFeng R, Hu X, Garrison SP., et al. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood 2010; 115: 3472-3480
35. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ., et al. p53- And drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038
36. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L., et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- And glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131-4138
37. Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J., et al. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev 2010; 24: 1602-1607
38. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 1999; 96: 14943-14948
39. Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene 2008; 27: S84-S92
40. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9: 357-359
41. Anders S, Pyl PT, Huber W. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31: 166-169
42. Law CW, Chen Y, Shi W, Smyth GK. Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014; 15: R29
43. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550
44. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Porta Della MG., et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24: 756-764